Has everyone read BTA's US corporate presentation - it's really well put together- very exciting indeed -http://www.biota.com.au/uploaded/154/1021614_681001uscorporatepresenta.pdf
love this section -
Stockpile market: growth driver �� The stockpile is ~US$8B globally and has been built over 4/5 years �� Stockpile initiated in 2004 by World Health Organization (WHO) �� Approx 60 countries intend to/or carry stockpiles �� WHO recommended the initial size of national stockpiles �� One course for 25% of population �� U.S. stockpile has not achieved that target currently ~22%; c.f. France 33%, UK 35%(intention to 50%), Australia 55%. �� WHO recommends increasing percentage coverage of the population as capacity/funding permits �� Relenzas percentage of the stockpile is increasing due to: �� Drug interactions and side effects with oseltamivir �� Concerns of oseltamivir resistance �� To date, 28 H1N1 pandemic viruses resistant to oseltamivir have been detected (now 206 ) and characterized worldwide** �� All of these viruses show the same H275Y mutation that confers resistance to oseltamivir, but not to zanamivir �� Rebalancing from 15:85 Relenza:Tamiflu towards 50:50 *
BTA Price at posting:
$2.07 Sentiment: LT Buy Disclosure: Held
